A significant difference was noted when comparing ACTA2 expression levels between WHO grade 3 and grade 4 gliomas: the ACTA2/RPL37 ratio was approximately fourfold higher in grade 4 gliomas, with a median of 1.31 (range: 0.11–11.35) compared to a median of 0.28 (range: 0.04–2.09) in grade 3 gliomas (Figure 4A, p = 0.002). The gene discussed is RPL37; the disease is central nervous system cancer.